Allergan breaks ground on $200 million expansion at Texas site
Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas.
The expansion will nearly double its current manufacturing space, adding 322,000 square feet to the existing facility. Upon completion, a further 100 full-time jobs will be added on site, with the option for expanding to 250 new jobs as the site reaches full utilisation. The new positions will range from chemists and microbiologists to process engineers and production and maintenance technicians.
The expansion will also add a new raw material dispensary, an automated bulk formulation suite and ten new state-of-the-art production lines. Expected to be completed by 2020, the Waco site will be capable of producing more than 40 different product formulations. The facility is currently Allergan’s flagship facility for its range of eye care products, including Restasis, Lumigan and Latisse.
Brent Saunders, president and CEO at Allergan, says: “Today’s groundbreaking marks an important milestone for Allergan, strengthening our commitment to our people, operations and the partnership we have built with Waco and the Central Texas communities for 27 years. This investment will add highly-skilled jobs to the Waco and Central Texas economies, elevate our manufacturing capabilities and increase our ability to provide more complex medicines to more physicians and their patients around the globe.”
In a companion supplement from the School of Business at Baylor University, Dr. Tom Kelly highlights the beneficial impacts of Allergan’s investment. His analysis found that the total economic impact of Allergan capital investment plus operations on the Central Texas economy is projected to be $522.3 million.
He comments: “We hope that Allergan serves as a benchmark for other companies looking for a business friendly community with a highly skilled workforce to consider relocating operations to Waco and the Central Texas area.”
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …
ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great …